3-(2-(4-哌啶基)乙基)-1H-吲哚盐酸盐 | 63845-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(2-(4-哌啶基)乙基)-1H-吲哚盐酸盐
• 中文别名: 盐酸吲达品
• 英文名称: Indalpine hydrochloride
• 英文别名: 3-(2-piperidin-4-ylethyl)-1H-indole;hydrochloride
• CAS: 63845-42-1
• 化学式: C15H21ClN2
• 分子量: 264.79
• InChiKey: GIPICJLTGNEIIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.92
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  32.4
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1(b)
• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  6.1(b)

文献信息

• Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases
  申请人：Combinatorx, Incorporated

  公开号：EP2070550A1

  公开（公告）日：2009-06-17

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

  本发明的特点是通过向患者单独或与一种或多种附加制剂联合使用四取代嘧啶嘧啶，治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有四取代嘧啶嘧啶的组合物与一种或多种附加制剂的组合物。
• Methods, compositions, and kits for the treatment of ophthalmic disorders
  申请人：CombinatoRx, Inc.

  公开号：EP2218442A1

  公开（公告）日：2010-08-18

  The invention features methods, compositions and kits comprising a corticosteroid and a non-steroidal immunophilin-dependent immunosuppressant for treating an ophthalmic disorder in a patient, wherein at least one of said corticosteroid and said non-steroidal immunophilin-dependent immunosuppressant is present at a low concentration, in particular wherein said corticosteroid is prednisolone acetate and said non-steroidal immunophilin-dependent immunosuppressant is cyclosporine A.

  本发明的特征是包含皮质类固醇和非类固醇免疫嗜血素依赖性免疫抑制剂的方法、组合物和试剂盒，用于治疗患者的眼科疾病、其中，所述皮质类固醇和所述非类固醇免疫嗜血素依赖性免疫抑制剂中至少有一种以低浓度存在，特别是所述皮质类固醇为醋酸泼尼松龙，所述非类固醇免疫嗜血素依赖性免疫抑制剂为环孢素 A。
• Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
  申请人：Nlife Therapeutics S.L.

  公开号：EP2380595A1

  公开（公告）日：2011-10-26

  The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleuc acid toi cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.

  本发明提供了一种共轭物，该共轭物包含(i)与靶核酸序列互补的核酸，该核酸的表达可防止或减少靶核酸的表达；(ii)能够与神经递质转运体高亲和力结合的选择剂。本发明的共轭物可用于将核酸递送至相关细胞，从而治疗需要下调靶核酸编码蛋白的疾病，也可用于将造影剂递送至细胞以进行诊断。
• Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
  申请人：nLife Therapeutics, S.L.

  公开号：US10125363B2

  公开（公告）日：2018-11-13

  The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.

  本发明提供了一种共轭物，该共轭物包含：(i) 一种选择性制剂，它能与一种或多种神经递质转运体特异性结合，这些神经递质转运体选自由多巴胺转运体（DAT）、5-羟色胺转运体（SERT）或去甲肾上腺素转运体（NET）组成的组、多巴胺转运体 (DAT)、5-羟色胺转运体 (SERT) 或去甲肾上腺素转运体 (NET)；(ii) 能够与靶分子特异性结合的核酸，该靶分子与神经递质转运体在同一细胞中表达，其中所述靶分子为 α-突触核蛋白或编码 α-突触核蛋白的 mRNA。本发明的共轭物可用于将核酸递送至相关细胞，从而治疗需要下调靶核酸编码蛋白的疾病，也可用于将成像剂递送至细胞以进行诊断。
• Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
  申请人：——

  公开号：US20040229849A1

  公开（公告）日：2004-11-18

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

  本发明的特点是通过向患者施用 SSRI 或其类似物或代谢物以及皮质类固醇或其他化合物来治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有 SSRI 或其类似物或代谢物和皮质类固醇或其他化合物的药物组合物，用于治疗或预防免疫炎症性疾病。